Mankind Pharma Ltd. Share Price

Overview

Mankind Pharma Ltd. share price is currently ₹2,584.18, up by ₹16.59 (0.65%) from its previous closing price of ₹2,567.59. The share price has gained 15.67% over the past month and gained 14.54% over the past year. The stock's 52-week low and high are ₹1,882.53 and ₹2,679.96, respectively. Mankind Pharma Ltd. has a market capitalisation of ₹ 1,09,039.77 Cr. The share price was last updated on 18 Nov 2026, 03:59 PM IST.

Mankind Pharma Ltd.
Mankind Pharma Ltd.
MANKIND
 ₹0.00
 ₹16.59
0.65%
Healthcare
 ₹0.00(%)1D

Updated: 18 Nov 2026, 03:59:47 pm IST

Market Data

Open Price

 ₹2,569.03

Prev. Close

 ₹2,567.59
 ₹2,566.10

Day Low

 ₹2,605.16

Day High

 ₹1,882.53

52 Week Low

 ₹2,679.96

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

47.58

Sector PE

45.69

PB Ratio

6.56

Sector PB

5.99

EPS

54.31

Dividend Yield

0.05

Today's Volume

365.282 K

5 Day Avg. Volume

394.504 K

PEG Ratio

-11.98

Market Cap.

₹ 1,09,039.77 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsInterim Dividend of 100% at ₹1/Share
08-Aug-202508-Aug-2025

Mutual Fund Ownership

Mutual Fund Holder
Sep 26
Shares held
Oct 26
Shares held
SBI Large Cap Fund - Regular Plan - Growth40.73 Lac
40.73 Lac
no change
Nippon India Growth Mid Cap Fund - Growth Option39.00 Lac
39.00 Lac
no change
HDFC Large Cap Fund - Growth27.39 Lac
27.39 Lac
no change
Nippon India Large Cap Fund - Growth21.35 Lac
22.62 Lac
(5.97%)
Aditya Birla Sun Life Flexi Cap Fund - Regular Plan - Growth20.72 Lac
21.00 Lac
(1.33%)

About Mankind Pharma Ltd. 👋

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, Rivotril, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Aalgo Breaths

Aalgo Breaths

9 Nov • 10:51 PM · SEBI-Registered Analyst

Mankind Pharma Ltd. – Technical Analysis

MANKIND Mankind Pharma is showing strong bullish momentum on the daily chart after recovering from its important support zone around ₹2,190–₹2,250. The stock is currently trading near ₹2,668, supported by a strong bullish candle and encouraging volume participation. The immediate support zone is placed at ₹2,637–₹2,600, followed by ₹2,549. On the upside, the stock may face resistance around ₹2,725–₹2,750. A sustained breakout above this zone could open the way towards ₹2,813 and ₹2,901. Momentum indicators are showing a positive trend, while RSI near 69 indicates strong buying interest. However, some short-term consolidation or profit booking cannot be ruled out. Overall Outlook: The technical structure remains bullish. Sustaining above key support levels may support further upside, while a decisive breakout above ₹2,750 could strengthen the positive outlook. Traders should follow proper risk management and wait for breakout confirmation.

See More
Rakesh Kumar Singhal

Rakesh Kumar Singhal

30 Oct • 10:58 AM · SEBI-Registered Analyst

MANKIND PHARMA Results Analysis-Q2FY2027

MANKIND Financial performance and key operating metrics (Consolidated) : Operating Revenue for Q2FY27 is Rs. 4,338 Crs., 17.33% growth YoY, Total Income is Rs. 4,433 Crs., 16.99% growth YoY, Gross Profit is Rs. 3,134 Crs., 18.92% growth YoY, EBITDA is Rs. 1,171 Crs., 27.13% growth YoY, EBITDA Margin is 27% improved by 208 Basis points YoY, PBT Rs. 929 Crs., 48.89% growth YoY, PAT Rs. 716 Crs., 37.67% growth YoY. On QoQ basis Op. Revenue is up by 7.62%, Total Income is up by 8.76%, EBITDA is up by 10.89%, PBT is up by 20.75% PAT is also up by 24.74%. Strong growth in base business as well as BSV speciality business. Margin growth is due to price hikes, richer chronic mix, lower R&D, operating leverage. Net debt ₹2,639 cr; net debt/adj EBITDA 0.6x. Company reiterated intent to reduce acquisition related debt by FY28. Domestic revenue: ₹3,657 cr, +14.8% YoY; with “16% growth in mankind core domestic, ex-consumer” and “mid-teen growth in BSV domestic,” partially offset by softer consumer. International revenue: ₹680 cr, +33% YoY. Growth decomposition: driven by both Mankind and BSV, supported by “branded specialty products and new US launches.”

See More
Manjushri Sharma

Manjushri Sharma

28 Oct • 2:21 PM · SEBI-Registered Analyst

MANKIND PHARMA PROFIT JUMPS 26% AS REVENUE GROWS 20%

MANKIND Mankind Pharma's Q2 Performance Highlights Strong Revenue and Profit Growth One of the important things I look for in pharmaceutical companies is whether revenue growth is translating into stronger profitability. Mankind Pharma reported second-quarter revenue of ₹3 145 crore an increase of 20% year-on-year. Net profit rose 26% to ₹582 crore while gross profit increased 36% to ₹813 crore. The company has delivered growth across these reported financial measures making the stock worth monitoring as investors assess the pharmaceutical sector's earnings outlook. What Caught My Attention? 1. Healthy Revenue Growth Revenue growth of 20% indicates a strong increase in reported sales. The sustainability of this growth will depend on product demand market share and the company's ability to expand its business. 2. Profitability Is Improving Net profit grew faster than revenue while gross profit increased by 36%. These figures are encouraging although investors should examine operating expenses and margins in the complete results to understand the underlying drivers. 3. What Could Influence the Stock? Future performance will depend on domestic pharmaceutical demand product launches competition pricing conditions and regulatory developments. My Market View I believe investors should distinguish between strong quarterly earnings and an attractive stock valuation. A company can report impressive numbers but its share price may react differently depending on market expectations. For Mankind Pharma I would monitor the stock's reaction to the results trading volumes and technical structure to assess whether buying interest is strengthening. The key takeaway: Strong earnings growth deserves attention but valuation business sustainability and price confirmation should remain part of the analysis.

See More
InvestAce Capital

InvestAce Capital

27 Oct • 2:22 PM · SEBI-Registered Analyst

Mankind Pharma reports 39% quarterly profit growth

Mankind Pharma MANKIND ND reported approximately 39% year-on-year growth in consolidated net profit to ₹712 crore for the September 2026 quarter, supported by growth across its pharmaceutical operations. Revenue increased approximately 17% to ₹4,338 crore, reflecting continued business expansion and demand across its healthcare portfolio. India's growing healthcare requirements and pharmaceutical consumption could support future growth opportunities. However, profitability will depend on product demand, regulatory compliance, pricing pressures and operating efficiency. What I'm watching: Domestic pharmaceutical sales, product launches, revenue growth, operating margins and regulatory developments. Stance: Strong quarterly earnings and revenue expansion; sustainable profitability and consistent business growth remain key factors to assess. Disclosure: This post is for educational purposes only and is not investment advice or a buy/sell recommendation. Disclose any holding or interest before publishing.

See More
Vipin Dixena

Vipin Dixena

27 Oct • 2:12 PM · SEBI-Registered Analyst

Mankind Pharma Q2 FY27: Profit Jumps 38% to ₹716 Crore

Mankind Pharma ( MANKIND ) delivered a strong Q2 FY27 performance, with profit growing faster than revenue and operating margins improving. The results reflect healthy demand in its domestic pharmaceutical business, strength in chronic therapies and robust export growth. Key Q2 FY27 Highlights - Net profit: ₹716 crore, up 37.7% year-on-year. - Revenue from operations: ₹4,338 crore, up 17.3% YoY. - EBITDA: ₹1,175 crore, up 27.2% YoY. - EBITDA margin: Expanded to 27.1% from approximately 25% a year ago. - Domestic pharmaceutical business: Grew 15.9%, excluding consumer healthcare. - International business: Revenue increased 33% YoY. - Chronic therapies: Cardiac and anti-diabetes brands grew approximately 19% and 16%, respectively. What Is Driving the Growth? Mankind Pharma's domestic business outperformed the Indian Pharmaceutical Market, supported by demand for chronic and acute therapies. Its specialty portfolio, including Bharat Serums and Vaccines (BSV), and international operations also contributed to growth. Importantly, EBITDA grew faster than revenue, indicating improved operating profitability. However, the consumer healthcare business faced relatively subdued category-level demand, making this an area to monitor. My View Mankind Pharma's Q2 results are encouraging because the company has delivered growth across revenue, earnings and operating margins. The performance of chronic therapies and the 33% growth in international revenue provide additional support to its growth outlook. The company's entry into next-generation CAR-T therapies through its acquisition of Armed Cell Therapeutics also adds a potential long-term growth avenue, although its commercial contribution will take time to assess. Overall, the results strengthen the operating-growth narrative, but investment decisions should also consider the stock's valuation and the sustainability of earnings growth.

See More
Ujvin Nevatia

Ujvin Nevatia

27 Oct • 1:45 PM · SEBI-Registered Analyst

Mankind Pharma profit rises 38% as margins expand

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 Mankind Pharma Limited ( MANKIND ) reported consolidated net profit of ₹716 crore in Q2 FY27, up 37.7% year-on-year from ₹520.2 crore. Revenue from operations grew 17.3% to ₹4,337.9 crore. What happened? EBITDA increased 27.2% to ₹1,175 crore, while the EBITDA margin expanded by 210 basis points to 27.1%. Domestic revenue, excluding consumer healthcare, grew 15.9%, supported by demand for chronic therapies. Cardiac and anti-diabetes medicines recorded strong growth. Export revenue increased 32.7% to ₹681 crore, while the consumer healthcare business grew a modest 1.2%. Why does it matter? Profit grew faster than revenue, indicating improved operating leverage and stronger margins. Domestic pharmaceutical demand and export growth supported performance, although the slower consumer healthcare business remains an area to monitor. My view The quarter reflects healthy growth across core pharmaceuticals and international markets, alongside improved profitability. The key challenge is sustaining margin expansion while strengthening consumer healthcare and integrating newer businesses. What I am watching next I would track domestic volume growth, chronic therapy performance, export growth, consumer healthcare sales and EBITDA margins to assess the sustainability of earnings. No Recommendations Source: The Economic Times Disclosure: I, my entity, associates or relatives do not have any holding, position or other material interest in Mankind Pharma Limited.

See More

News & Events

Frequently Asked Questions

What is the share price of Mankind Pharma Ltd.?

What is the market cap of Mankind Pharma Ltd.?

Should I buy Mankind Pharma Ltd. stock now?

What is the 52 week high and low of Mankind Pharma Ltd.?

Is the Mankind Pharma Ltd. stock good to buy?

Is Mankind Pharma Ltd. a good buy for the long term?

Is Mankind Pharma Ltd. overvalued or undervalued?

What is the PE and PB ratio of Mankind Pharma Ltd.?

Start Now